Evaluation of the Case–Crossover (CCO) Study Design for Adverse Drug Event Detection

Zachary Burningham (), Tao He, Chia-Chen Teng, Xi Zhou, Jonathan Nebeker and Brian C. Sauer
Additional contact information
Zachary Burningham: Decision-Enhancement and Analytic Sciences (IDEAS) Center
Tao He: Decision-Enhancement and Analytic Sciences (IDEAS) Center
Chia-Chen Teng: Decision-Enhancement and Analytic Sciences (IDEAS) Center
Xi Zhou: Decision-Enhancement and Analytic Sciences (IDEAS) Center
Jonathan Nebeker: Decision-Enhancement and Analytic Sciences (IDEAS) Center
Brian C. Sauer: Decision-Enhancement and Analytic Sciences (IDEAS) Center

Drug Safety, 2017, vol. 40, issue 9, No 5, 789-798

Abstract: Abstract Introduction The case–crossover (CCO) design was originally intended to study exposures characterized as intermittent with acute effects. The performance of the CCO design is not well characterized under alternative exposure and outcome relationships. Objective The purpose of this study was to evaluate the ability of the CCO to identify simulated treatment effects under different drug exposures and outcomes relationships while varying the duration of the 1:1 matched risk and control windows. Methods The simulated data were obtained from the Observational Medical Dataset Simulator, version 2 (OSIM2). The area under the receiver operator characteristic curve (AUC) was calculated to compare CCO performance across outcome types, simulated relative risk (RR), and duration of risk and control windows. Results The AUC for acute outcomes was higher for shorter risk and control windows and improved with higher simulated RR. For example, the AUC for the simulated RR of 4 was 0.95 for a 30-day window length and 0.78 for a 360-day window length. The AUC for the accumulative outcomes increased with longer risk and control windows and stronger simulated RR. For example, the AUC for the simulated RR of 4 was 0.85 for a 360-day window length and 0.23 for a 30-day window length. Risk and control window lengths did not appear to sufficiently alter the AUC for insidious onset outcomes. Conclusions The CCO performed best for acute-onset outcomes, but may be useful for exploring adverse outcomes with accumulative effects. Careful consideration must be given to the hypothesized drug exposure and outcome distribution because specification of risk and control window duration affects CCO performance.

Keywords: Window Length; Condition Pair; Relative Risk Estimate; Discordant Pair; Central Nervous System Dysfunction (search for similar items in EconPapers)
Date: 2017
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-017-0540-3 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:40:y:2017:i:9:d:10.1007_s40264-017-0540-3

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-017-0540-3

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().